CD70 and neoplasm: Consistent with the in vitro results, CD70-KO did not alter the in vivo tumorigenicity of NPC in immunodeficient NSG mice (Fig. 3r), but led to significant tumor shrink in humanized NSG mice (Fig. 3s), further confirming an inhibitory role of CD70 on anti-tumor immunity.